Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wan-Long Chuang

Showing results (191-200 of 456) with videos related to

Pageof 46
Sort By:
The Kaohsiung Journal of Medical Sciences|November 5, 2020
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatmentTzu-Sheng Cheng, Po-Cheng Liang, Chung-Feng Huang, et al.
The Kaohsiung Journal of Medical Sciences|March 3, 2020
Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodulesZu-Yau Lin, Jing-Houng Wang, Ming-Lun Yeh, et al.
Hepatology International|July 24, 2015
APASL consensus statements and management algorithms for hepatitis C virus infectionMasao Omata, Tatsuo Kanda, Ming-Lung Yu, et al.
Plos One|January 4, 2013
Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirinMing-Lung Yu, Chen-Hua Liu, Chung-Feng Huang, et al.
Journal of Gastroenterology and Hepatology|July 5, 2014
Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infectionRichard A Colvin, Tawesak Tanwandee, Teerha Piratvisuth, et al.
Journal of Hepatology|August 26, 2014
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathyPatrick Marcellin, Karsten Wursthorn, Heiner Wedemeyer, et al.
Journal of the Chinese Medical Association : JCMA|April 5, 2019
Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis CBatbold Batsaikhan, Ming-Ying Lu, Ming-Lun Yeh, et al.
Gastroenterology|December 17, 2009
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infectionJohn McHutchison, Zachary Goodman, Keyur Patel, et al.
Journal of Gastroenterology and Hepatology|November 28, 2002
Clinical characteristics and distribution of genotypes of TT virus infection in a hepatitis C virus-hyperendemic township of a hepatitis B virus-endemic country (Taiwan)Chia-Yen Dai, Ming-Lung Yu, Cheng Hou, et al.
Clinical Therapeutics|February 14, 2007
Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictorsChia-Yen Dai, Wan-Long Chuang, Nai-Jen Hou, et al.
Pageof 46

Showing results (191-200 of 456) with videos related to

Sort By:
Pageof 46
The Kaohsiung Journal of Medical Sciences|November 5, 2020
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatmentTzu-Sheng Cheng, Po-Cheng Liang, Chung-Feng Huang, et al.
The Kaohsiung Journal of Medical Sciences|March 3, 2020
Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodulesZu-Yau Lin, Jing-Houng Wang, Ming-Lun Yeh, et al.
Hepatology International|July 24, 2015
APASL consensus statements and management algorithms for hepatitis C virus infectionMasao Omata, Tatsuo Kanda, Ming-Lung Yu, et al.
Plos One|January 4, 2013
Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirinMing-Lung Yu, Chen-Hua Liu, Chung-Feng Huang, et al.
Journal of Gastroenterology and Hepatology|July 5, 2014
Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infectionRichard A Colvin, Tawesak Tanwandee, Teerha Piratvisuth, et al.
Journal of Hepatology|August 26, 2014
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathyPatrick Marcellin, Karsten Wursthorn, Heiner Wedemeyer, et al.
Journal of the Chinese Medical Association : JCMA|April 5, 2019
Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis CBatbold Batsaikhan, Ming-Ying Lu, Ming-Lun Yeh, et al.
Gastroenterology|December 17, 2009
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infectionJohn McHutchison, Zachary Goodman, Keyur Patel, et al.
Journal of Gastroenterology and Hepatology|November 28, 2002
Clinical characteristics and distribution of genotypes of TT virus infection in a hepatitis C virus-hyperendemic township of a hepatitis B virus-endemic country (Taiwan)Chia-Yen Dai, Ming-Lung Yu, Cheng Hou, et al.
Clinical Therapeutics|February 14, 2007
Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictorsChia-Yen Dai, Wan-Long Chuang, Nai-Jen Hou, et al.
Pageof 46